WuXi Biologics will be attending BIO International 2019 Click Here to Schedule a Meeting

Biologic Products DNA to IND Timeline in 9 Months – Yes it can be done! Click here to read a story featuring Jie Chen, Vice President of CMC Management, WuXi Biologics 

WuXi Biologics Successfully Completed First FDA Routine GMP Inspection Read More WuXi Biologics to be the first biologics company in China approved by both the U.S. FDA and EMA Read More WuXi Biologics Commenced Construction of a 48,000 L Integrated Manufacturing Center for Innovative Biologics in Chengdu Read More WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity Read More WuXi Biologics and I-Mab Biopharma Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs Read More WuXi Biologics and NBE-Therapeutics announce comprehensive ADC development and manufacturing partnership Read More ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Novel Immune Check Point Bispecifics for $220 Million Read More WuXi Biologics and Amicus Sign Exclusive Manufacturing Partnership Read More WuXi Biologics Congratulates Amicus on Receiving FDA Breakthrough Therapy Designation for AT-GAA Read More

See a presentation about our WuXiBody ™ bispecific antibody platform at these events (Click below for details) June 11-13, 2019 June 18-20, 2019 August 5-9, 2019 Capacity Strategies: The Strategies Behind Choosing Between Large-Scale and Single-Use Investments Viral Safety in Biomanufacturing Ask the Expert Continuous Manufacturing Scale-Out vs. Scale-Up GMP Manufacturing WuXi Biologics Case Studies WuXi Biologics Perspectives WuXi Biologics wins 2019 CMO Leadership Awards in all six core categories Read More WuXi Biologics receive's "Asia's Best CMO of 2018" award from IMAPAC Read More ‌

‌ ‌